These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36221115)

  • 21. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic and predictive biomarkers for coronary artery disease.
    Dong C; Chen J; Zheng J; Liang Y; Yu T; Liu Y; Gao F; Long J; Chen H; Zhu Q; He Z; Hu S; He C; Lin J; Tang Y; Zhu H
    Clin Epigenetics; 2020 Jan; 12(1):17. PubMed ID: 31964422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas.
    Bhagavathi S; Sharathkumar A; Hunter S; Sung L; Kanhere R; Venturina MD; Wilson JD
    Clin Neuropathol; 2008; 27(1):13-20. PubMed ID: 18257470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma.
    Cai Z; Zhang J; He Y; Xia L; Dong X; Chen G; Zhou Y; Hu X; Zhong S; Wang Y; Chen H; Xie D; Liu X; Liu J
    ESMO Open; 2021 Feb; 6(1):100021. PubMed ID: 33508734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia.
    Shao J; Wang S; West-Szymanski D; Karpus J; Shah S; Ganguly S; Smith J; Zu Y; He C; Li Z
    Sci Rep; 2022 Jul; 12(1):12410. PubMed ID: 35859008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers.
    Li W; Zhang X; Lu X; You L; Song Y; Luo Z; Zhang J; Nie J; Zheng W; Xu D; Wang Y; Dong Y; Yu S; Hong J; Shi J; Hao H; Luo F; Hua L; Wang P; Qian X; Yuan F; Wei L; Cui M; Zhang T; Liao Q; Dai M; Liu Z; Chen G; Meckel K; Adhikari S; Jia G; Bissonnette MB; Zhang X; Zhao Y; Zhang W; He C; Liu J
    Cell Res; 2017 Oct; 27(10):1243-1257. PubMed ID: 28925386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
    Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
    Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum cell-free DNA concentration as a possible prognostic marker in newly diagnosed diffuse large B-cell lymphoma.
    Shirouchi Y; Mishima Y; Takayama T; Minowa S; Ishihara Y; Tamba M; Hirano M; Onda N; Takeuchi K; Maruyama D
    Biomed Res; 2022; 43(4):99-106. PubMed ID: 35989290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylation silencing CDH23 is a poor prognostic marker in diffuse large B-cell lymphoma.
    Cao B; Guo X; Huang L; Wang B; Wang W; Han D; Zhang W; Zhong K
    Aging (Albany NY); 2021 Jul; 13(13):17768-17788. PubMed ID: 34252883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin.
    Kim SH; Cheong JW; Park KH; Kim TS; Yang WI
    Arch Pathol Lab Med; 2007 Mar; 131(3):457-67. PubMed ID: 17516749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor classification and is a positive prognostic marker.
    Azizgolshani N; Petersen CL; Chen Y; Levy JJ; Salas LA; Perreard L; Nguyen LN; Christensen BC
    Clin Epigenetics; 2021 Sep; 13(1):176. PubMed ID: 34538273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.
    Twa DDW; Mottok A; Savage KJ; Steidl C
    Blood Rev; 2018 May; 32(3):249-255. PubMed ID: 29289361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of genome-wide 5-hydroxymethylation of blood samples stored in different anticoagulants: opportunities for the expansion of clinical resources for epigenetic research.
    Gao L; Zhang Z; Cui XL; West-Szymanski D; Ye C; He C; Zhang W; Bissonnette M
    Epigenetics; 2023 Dec; 18(1):2271692. PubMed ID: 37898998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.
    Song MK; Chung JS; Joo YD; Lee SM; Oh SY; Shin DH; Yun EY; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ
    J Neurooncol; 2011 Sep; 104(3):825-31. PubMed ID: 21380743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era.
    Jing XM; Yu JR; Luo YK; Zhang SC; Liu JF; Li L; Wu P; Zhang ZH
    Leuk Res; 2017 Sep; 60():89-93. PubMed ID: 28772206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 39. [MGMT expression in primary central nervous system diffuse large B cell lymphoma and its relationship with prognosis].
    Shi QY; Feng X; Wang JJ; Wang X; Bao W; Ma J; Shi QL
    Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):850-853. PubMed ID: 28056300
    [No Abstract]   [Full Text] [Related]  

  • 40. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
    Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
    Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.